NMRA Q3 2023 Earnings — Neumora Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

NMRANeumora Therapeutics, Inc. Common Stock

$586M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$57M

Net Income

-$53M

EPS (Diluted)

$-0.34

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$48M

Free Cash Flow

-$48M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$545M

Total Liabilities

$32M

Stockholders' Equity

$513M

Cash & Equivalents

$412M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$57M	-$31M	-85.8%
Net Income	-$53M	-$29M	-80.7%